Exane Derivatives’s Sensata Technologies ST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
$661 Hold
16
﹤0.01% 546
2022
Q1
$814 Hold
16
﹤0.01% 820
2021
Q4
$987 Hold
16
﹤0.01% 711
2021
Q3
$876 Hold
16
﹤0.01% 877
2021
Q2
$913 Hold
16
﹤0.01% 885
2021
Q1
$927 Hold
16
﹤0.01% 743
2020
Q4
$844 Hold
16
﹤0.01% 694
2020
Q3
$690 Hold
16
﹤0.01% 652
2020
Q2
$596 Hold
16
﹤0.01% 596
2020
Q1
$463 Hold
16
﹤0.01% 605
2019
Q4
$834 Hold
16
﹤0.01% 559
2019
Q3
$801 Hold
16
﹤0.01% 551
2019
Q2
$784 Hold
16
﹤0.01% 568
2019
Q1
$720 Hold
16
﹤0.01% 523
2018
Q4
$717 Hold
16
﹤0.01% 586
2018
Q3
$798 Hold
16
﹤0.01% 558
2018
Q2
$769 Buy
+16
New +$833 ﹤0.01% 548
2017
Q3
Sell
-1
Closed -$43 639
2017
Q2
$43 Hold
1
﹤0.01% 596
2017
Q1
$44 Hold
1
﹤0.01% 523
2016
Q4
$39 Hold
1
﹤0.01% 586
2016
Q3
$39 Hold
1
﹤0.01% 572
2016
Q2
$35 Hold
1
﹤0.01% 509
2016
Q1
$39 Hold
1
﹤0.01% 560
2015
Q4
$46 Sell
1
-5
-83% -$230 ﹤0.01% 472
2015
Q3
$266 Buy
+6
New +$290 ﹤0.01% 460

Other funds holding ST

Exane Derivatives's ST Position: Q2 2022 in Review

Exane Derivatives held its Sensata Technologies (ST) position steady in Q2 2022 at 16 shares worth $661. The position accounts for ﹤0.01% of the portfolio, ranked #546.

Exane Derivatives first reported a position in ST in Q3 2015 and has held it in 25 quarters since. The position peaked at $987 in Q4 2021. 344 funds tracked by Wall St. Rank hold ST as of Q2 2022.

  • Exane Derivatives held 16 shares of Sensata Technologies worth $661 as of Q2 2022.
  • Exane Derivatives left its Sensata Technologies share count unchanged in Q2 2022.
  • Sensata Technologies made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #546 holding.
  • Exane Derivatives first reported a position in Sensata Technologies in Q3 2015 and has held it in 25 quarters since.
  • Exane Derivatives's Sensata Technologies position peaked at $987 in Q4 2021.
  • 344 funds tracked by Wall St. Rank held Sensata Technologies as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.